Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2020
Reporting Period: Quarterly and fiscal year ended December 31, 2019.
Context: This filing announces the issuance of a press release (Exhibit 99.1) detailing financial results for the period ended December 31, 2019. The company is an emerging growth company incorporated in Virginia.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed figures. Consequently, specific numerical values for the following metrics are not present in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for these metrics; they are contained within the referenced Exhibit 99.1.
Material Changes and Guidance
Guidance and Outlook: The filing explicitly references forward-looking statements regarding full-year 2020 guidance for:
- Xtampza ER revenues
- Nucynta Franchise revenues
- Total operating expense
- Non-GAAP adjusted income
Material Changes: No specific historical comparisons or material changes in financial condition are detailed in this text, as the specific results are deferred to the attached press release.
Risks and Contingencies
Management highlights substantial risks and uncertainties that could cause future results to differ from expectations, including:
- Regulatory: Ability to maintain product approvals and comply with DEA regulations.
- Commercial: Market acceptance, reimbursement contracts, and competition.
- Legal: Patent infringement litigation, specifically mentioning Purdue Pharma, L.P. and Teva Pharmaceuticals USA, Inc.
- Operational: Supply chain security for active pharmaceutical ingredients and third-party manufacturer performance.
- Financial: Accuracy of expense estimates and the potential need for additional financing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, profit, and cash flow figures for Q4 and FY 2019.
- Verify the specific numerical targets for the 2020 guidance regarding Xtampza ER and Nucynta Franchise revenues.
- Assess the status of ongoing litigation with Purdue Pharma and Teva Pharmaceuticals.
- Confirm the company's current liquidity position and capital requirements as detailed in the full press release.